Léa Sorret

Léa Sorret

Auto-generated profile, based on publicly available information

Léa Sorret

Drug Product Services, Lonza AG, Hochbergerstrasse 60G, 4057 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
ECELIA CAPPELLETTO
ELIA CAPPELLETTO
SKStanley C. Kwok
Stanley C. Kwok
LSLéa Sorret
Léa Sorret
NFNathalie Fuentes
Nathalie Fuentes
AMAnnette M. Medina
Annette M. Medina
GPGiorgia De Paoli
Giorgia De Paoli
This article evaluates the current gaps around the impact of post-manufacturing processes on the product qualities of protein-based biologics, with a focus on user centricity. It includes the evaluation of the regulatory guidance available, describes a collection of scientific literature and case studies to showcase the impact of post-manufacturing stresses on product and dosing solution quality. It also outlines the complexity of clinical handling and the need for communication, and alignment between drug providers, healthcare professionals, users, and patients. Regulatory agencies provide clear expectations for drug manufacturing processes, however, guidance supporting post-product manufacturing handling is less defined and often misaligned. This is problematic as the pharmaceutical products experience numerous stresses and processes which can potentially impact drug quality, safety and efficacy. This article aims to stimulate discussion amongst pharmaceutical developers, health care providers, device manufacturers, and public researchers to improve these processes. Patients and caregivers' awareness can be achieved by providing relevant educational material on pharmaceutical product handling.

20 October 2023 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
MKMarkus Kardorff
Markus Kardorff
HMHanns-Christian Mahler
Hanns-Christian Mahler
JHJörg Huwyler
Jörg Huwyler
LSLéa Sorret
Léa Sorret

15 May 2024 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
LSLéa Sorret
Léa Sorret
WTWei Han Tan
Wei Han Tan
SVSenta Voss
Senta Voss
PFPatrick Favrod
Patrick Favrod
PCPascal Chalus
Pascal Chalus
MWMatthias Winzer
Matthias Winzer

7 February 2023 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MKMarkus Kardorff
Markus Kardorff
HMHanns-Christian Mahler
Hanns-Christian Mahler
JHJörg Huwyler
Jörg Huwyler
DJDhananjay Jere
Dhananjay Jere
LSLéa Sorret
Léa Sorret

4 June 2026 in AAPS PharmSciTech
Verified
Journal Article
Open access
LSLéa Sorret
Léa Sorret
MNMamiko Ninomiya
Mamiko Ninomiya
NHNils Hillebrandt
Nils Hillebrandt
DSDavid Schmitt
David Schmitt
ACArundhati Chattopadhyay
Arundhati Chattopadhyay
OMOrla McGarvey
Orla McGarvey
Antibody–drug conjugates (ADCs) combine the target specificity of monoclonal antibodies with the potency of cytotoxic small molecules, offering enhanced therapeutic potential. However, their inherent structural complexity, arising from the interplay of antibody, linker, and payload, introduces unique challenges for drug product (DP) development, stability, and scalability requiring tailored approaches to maintain the quality target product profile throughout the product lifecycle. This review summarizes key formulation and process development considerations for ADCs, with an emphasis on aspects that are particularly distinctive for ADC drug products. Critical degradation risks, such as photo- and heat-induced degradation, are discussed in the context of formulation screening, formulation excipients and primary packaging selection, and DP process design. Basic considerations on analytical tools used to identify and monitor critical quality attributes are provided. Lyophilization strategies, essential for the stability of commercialized ADCs, are recommended using Design of Experiments and modeling approaches. Furthermore, robust DP process control strategies during scale-up are reviewed with a focus on lyophilization, the application of Quality by Design (QbD) principles, and risk-based methodologies to address ADC‑specific challenges. Finally, the review explores the transition from early development to late-phase clinical and commercial stages, underscoring the need for evolving control strategies. Overall, it provides an overview of current practices and challenges in ADC formulation and DP process development, offering strategies to navigate these complexities based on literature and insights from approved ADCs.

19 March 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
LSLéa Sorret
Léa Sorret
NFNathalie Fuentes
Nathalie Fuentes
LNLara Nonis
Lara Nonis
VDVera Damuzzo
Vera Damuzzo
GVGiuliana Vozza
Giuliana Vozza
SKStanley C. Kwok
Stanley C. Kwok
Biologic drugs require specialized handling to maintain efficacy and safety, yet there is limited data on how healthcare professionals access information and comply with drug handling regulations. A 16-question survey was used to assess professional perspectives on procedures and regulations around biologic drugs handling. The survey yielded 36 valid responses. Participants included pharmacists, nurses, doctors, drug developers, academics and educators, primarily practicing in European countries. Information source and regulatory familiarity varied by professional role: pharmacists prioritized drug registries, doctors and nurses relied more on peer network and institutional guidance, and academics and drug developers utilized scientific literature and data. Respondents across roles recognized EU, national laws, and facility rules as strong influencers of biologic drugs handling procedures and approximately two-thirds reported rare conflicts between national regulations and EU guidance. However, over 90% of participants expressed a need for additional guidelines around drug safety, preparation, administration, with pharmacists recognized as key stakeholder. These findings provide insights into how different healthcare professionals apply information regarding drug handling, underscoring the need for focused, role-specific education, clear instructions, and regulatory guidance. While national and EU regulatory alignment appears strong, clearer guidelines and cross-professional communication could improve patient care, minimize risks, and maintain compliance.